NP PHARMA
ActiveFrom the official registers: KBO 1 annual account at the National Bank publications in the Belgian Official Gazette
Summary
NP PHARMA has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €40,694 and a net result of €37,694. Its solvency ranks better than 77% of 22,679 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Directors
Mandate history
- Board
| Name | Functions and periods |
|---|---|
| PIZZOFERRATO Nicolas |
|
How the board is organised
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Un ou plusieurs administrateurs, personnes physiques ou morales,actionnaires ou non”“Assemblée générale”
Oversight and winding up
- Statutory auditorA statutory auditor is a registered auditor who checks the accounts; small companies need not have one. According to the deed, the legal criteria do not require one here.
- No statutory auditor
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Pouvoirs les plus étendus conférés par articles 2:87 et suivants CSA, assemblée générale le cas échéant”
Articles of association, deed of 17-02-2025
Owners and capital
Capital and shareholders
- PIZZOFERRATO Nicolas 3,000 shares (100%) · €3,000 in cash
- 17-02-2025 Incorporation · €3,000 · 3,000 shares
Shares according to the articles of association
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Nominatives, 3000”
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- One provision in the deed
Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.
Articles of association, deed of 17-02-2025 (in French)